Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Reply to correspondence letter by Luis Ignacio Gonzalez-Granado

Dear Sir,

We wish to thank Dr Luis Ignazio Gonzales-Granado for his valuable comments on our paper entitled “Purine nucleoside phosphorylase deficiency with fatal course in two sisters” [1]. To the best of our knowledge, sclerosing cholangitis has never been described in patients with purine nucleoside phosphorylase deficiency, which itself is a very rare condition. We used a modified version of Kinyoun’s acid-fast staining method for detecting Cryptosporidium parvum. For the time being, we are unable to use PCR to identify this pathogen. As to the antifungal treatment, for financial reasons linked to the patient’s health care insurance, we could not prescribe in our patient the voriconazole, caspofungin, nor the combination of both drugs.

Reference

  1. 1.

    Aytekin C, Dogu F, Tanir G et al (2009) Purine nucleoside phosphorylase deficiency with fatal course in two sisters. Eur J Pediatr. doi: 10.1007/s00431-009-1029-6

Download references

Author information

Correspondence to Caner Aytekin.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Aytekin, C., Dogu, F. & Ikinciogullari, A. Reply to correspondence letter by Luis Ignacio Gonzalez-Granado. Eur J Pediatr 169, 519 (2010). https://doi.org/10.1007/s00431-009-1063-4

Download citation

Keywords

  • Nucleoside
  • Cholangitis
  • Voriconazole
  • Phosphorylase
  • Rare Condition